We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+9.87%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$469K
Cap. Flow
-$27M
Cap. Flow %
-9.03%
Top 10 Hldgs %
39.8%
Holding
92
New
15
Increased
30
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$9.95M
2
EHC icon
Encompass Health
EHC
+$8.69M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.99M
4
BIIB icon
Biogen
BIIB
+$5.15M
5
PFE icon
Pfizer
PFE
+$4.29M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$10.6M
2
GMED icon
Globus Medical
GMED
+$10.3M
3
MRK icon
Merck
MRK
+$10.2M
4
BDX icon
Becton Dickinson
BDX
+$8.54M
5
STJ
St Jude Medical
STJ
+$7.48M

Sector Composition

Rank Sector Weight
1 Healthcare 89.39%
2 Financials 3.11%
3 Technology 0.63%
4 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
51
Cardinal Health
CAH
$53.9B
$1.56M 0.52%
17,500
+1,800
+11% +$153K
BDSI
52
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.33M 0.45%
278,380
+254,880
+1,085% +$1.44M
GMED icon
53
Globus Medical
GMED
$10.7B
$1.24M 0.42%
44,629
-409,100
-90% -$10.3M
HZNP
54
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.21M 0.41%
55,940
-64,760
-54% -$1.26M
HUM icon
55
Humana
HUM
$43.7B
$1.2M 0.4%
6,698
-15,100
-69% -$2.65M
RAD
56
DELISTED
Rite Aid Corporation
RAD
$1.15M 0.39%
7,358
+5,383
+273% +$797K
NSTG
57
DELISTED
NanoString Technologies, Inc.
NSTG
$1.12M 0.38%
+76,311
New +$1.12M
HMSY
58
DELISTED
HMS Holdings Corp.
HMSY
$1.05M 0.35%
85,163
-294,700
-78% -$3.35M
XENT
59
DELISTED
Intersect ENT, Inc
XENT
$900K 0.3%
+40,000
New +$791K
BHC icon
60
Bausch Health
BHC
$2.58B
$793K 0.27%
7,800
-3,700
-32% -$416K
ELV icon
61
Elevance Health
ELV
$81.5B
$762K 0.25%
+5,467
New +$753K
CRL icon
62
Charles River Laboratories
CRL
$11.2B
$690K 0.23%
8,588
+2,088
+32% +$151K
DVA icon
63
DaVita
DVA
$15.4B
$661K 0.22%
9,489
-10,611
-53% -$777K
TVTY
64
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$659K 0.22%
51,211
-23,689
-32% -$288K
SSRG
65
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$629K 0.21%
68,333
-56,471
-45% -$503K
INCY icon
66
Incyte
INCY
$24.2B
$618K 0.21%
+5,700
New +$636K
JNJ icon
67
Johnson & Johnson
JNJ
$618B
$596K 0.2%
5,800
-54,100
-90% -$5.44M
ILMN icon
68
Illumina
ILMN
$31B
$557K 0.19%
+2,981
New +$481K
MDVN
69
DELISTED
MEDIVATION, INC.
MDVN
$556K 0.19%
+11,500
New +$496K
PTCT icon
70
PTC Therapeutics
PTCT
$5.68B
$480K 0.16%
14,800
-8,200
-36% -$241K
DERM
71
DELISTED
Dermira, Inc.
DERM
$456K 0.15%
+13,188
New +$379K
OCRX
72
DELISTED
Ocera Therapeutics, Inc.
OCRX
$428K 0.14%
137,093
-40,028
-23% -$137K
REGN icon
73
Regeneron Pharmaceuticals
REGN
$78.5B
$405K 0.14%
746
-1,654
-69% -$896K
WCG
74
DELISTED
Wellcare Health Plans, Inc.
WCG
$360K 0.12%
+4,604
New +$382K
ACAD icon
75
Acadia Pharmaceuticals
ACAD
$4.43B
$357K 0.12%
10,010
+310
+3% +$10.9K
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Endurant Capital Management held 92 positions worth $299M, down 0.16% from $300M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management withdrew a net $27M in Q4 2015, closing 15 positions and reducing 32 holdings. Its most notable exit was CR Bard Inc., an estimated $3.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Endurant Capital Management opened a new position in Pfizer worth $4.17M.

  • Endurant Capital Management's largest Q4 2015 buy was Pfizer: 136,282 shares worth $4.17M.
  • Endurant Capital Management added most to Zimmer Biomet in Q4 2015, an estimated $9.95M increase.
  • Endurant Capital Management's biggest Q4 2015 reduction was Thermo Fisher Scientific, cutting an estimated $10.6M.
  • Endurant Capital Management fully exited CR Bard Inc. in Q4 2015, selling an estimated $3.71M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $299M portfolio in Q4 2015.
  • Endurant Capital Management opened 15 new positions and closed 15 in Q4 2015.
  • Endurant Capital Management's portfolio value fell 0.16% quarter-over-quarter to $299M.

Based on Endurant Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.